Oxidative stress in psychiatric disorders: Pathophysiological insights and therapeutic perspectives

Authors

Abstract

Psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders are complex, multifactorial conditions with a significant global burden. In recent years, oxidative stress (OS) has gained increasing recognition as a central pathophysiological mechanism contributing to the onset and progression of these disorders. OS, defined by an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, disrupts cellular homeostasis and leads to neuronal damage, impaired synaptic plasticity, and neuroinflammation—all of which are key features in psychiatric illness. Accumulating evidence from clinical, preclinical, and neurobiological studies supports the association between redox dysregulation and psychiatric symptoms, as well as cognitive impairment and neuroprogression. Moreover, antioxidant-based therapies, including compounds such as N-acetylcysteine, omega-3 fatty acids, and vitamins C and E, have shown potential as adjunctive treatments by targeting oxidative pathways and modulating inflammatory and mitochondrial function. Despite these promising findings, challenges remain in standardizing OS biomarkers, establishing causality, and optimizing individualized treatment strategies. This review synthesizes current knowledge on the mechanisms linking OS to psychiatric disorders, evaluates the clinical evidence for antioxidant interventions, and highlights emerging directions for research and therapeutic innovation. A deeper understanding of oxidative biology in psychiatry holds the potential to inform novel diagnostic tools and guide the development of more targeted, mechanism-based treatments

Keywords

Introduction

Psychiatric disorders, including depression, schizophrenia, bipolar disorder, and anxiety disorders, are among the leading causes of disability worldwide, imposing a significant burden on individuals and healthcare systems alike ^1,2,3,4. Traditionally considered to be functional illnesses with predominantly psychosocial origins, psychiatric conditions are now increasingly recognized to have complex biological underpinnings involving neuroinflammation, mitochondrial dysfunction, and oxidative stress (OS) ^5,6. Emerging evidence suggests that OS may represent a common mechanistic pathway linking environmental stressors, genetic vulnerability, and neurobiological alterations observed in a wide array of psychiatric illnesses ^7,8.
OS is defined as a state of imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense systems of the body ^9,10. Although ROS are naturally generated during cellular respiration and play important roles in cell signaling and immune responses, excessive accumulation can damage lipids, proteins, and DNA, ultimately leading to cellular dysfunction and death ^11,12,13. The brain, due to its high oxygen consumption, abundant polyunsaturated fatty acids, and relatively limited antioxidant capacity, is particularly susceptible to oxidative damage. As such, OS has been implicated in the pathophysiology of various neurological and psychiatric conditions ¹⁴.
The relationship between OS and psychiatric disorders is bidirectional and multifactorial. On the one hand, chronic psychological stress, sleep disturbances, poor diet, and substance abuse—commonly observed in psychiatric populations—can lead to increased ROS generation and a compromised antioxidant defense system. On the other hand, oxidative imbalance may directly impair neuronal function and neuroplasticity, alter neurotransmitter metabolism, and promote neuroinflammation—all of which are central features of psychiatric illness ¹⁴. Moreover, mitochondrial dysfunction, which contributes to OS, has been consistently observed in postmortem and neuroimaging studies of individuals with mood and psychotic disorders ^15,16.
A growing body of clinical research supports the role of OS in psychiatric conditions ^15,17. Elevated levels of oxidative biomarkers have been reported in patients with schizophrenia, major depressive disorder, and bipolar disorder ^18,19,20. Concurrently, reductions in endogenous antioxidants such as glutathione (GSH), superoxide dismutase (SOD), and catalase have been observed ^21,22. These alterations are often correlated with illness severity, chronicity, and treatment response, suggesting that OS is not merely a secondary phenomenon but may play a pathogenic role. Furthermore, some antioxidant compounds—such as N-acetylcysteine (NAC), omega-3 fatty acids, and certain vitamins—have shown promise as adjunctive treatments, providing further support for a causative link ^23,24.
Despite accumulating evidence, the precise role of OS in psychiatric disorders remains to be fully elucidated. Confounding factors, heterogeneity in study design, and variability in biomarker measurement have posed significant challenges. Nonetheless, the exploration of redox biology in psychiatry holds substantial promise—not only for improving our understanding of disease mechanisms but also for identifying novel biomarkers and therapeutic targets. It opens the possibility of developing more personalized and biologically informed interventions that can enhance treatment outcomes in patients with psychiatric illness.
In this review, we aim to summarize the current knowledge regarding the biological basis of OS and its involvement in the pathophysiology of major psychiatric disorders. We will first provide an overview of the mechanisms underlying OS and the brain’s vulnerability to oxidative damage. Subsequently, we will examine the evidence linking OS to specific psychiatric conditions and evaluate the potential of antioxidant therapies. Finally, we will discuss the challenges and future directions in this rapidly evolving field.
Oxidative StressOS represents a fundamental pathophysiological process characterized by an imbalance between the production of ROS and the antioxidant defense mechanisms that neutralize them. This imbalance can lead to oxidative damage to vital biomolecules such as lipids, proteins, and nucleic acids, disrupting cellular homeostasis and contributing to the pathogenesis of a wide range of diseases, including psychiatric disorders ^{12,13,25,26,27,28,29,30,31,32}. ROS are chemically reactive molecules derived from molecular oxygen. Common ROS include superoxide anion (O₂•⁻), hydrogen peroxide (H₂O₂), and hydroxyl radical (•OH). While these species are often associated with cellular damage, they also play essential roles in normal physiological processes such as cell signaling, proliferation, and immune defense. In biological systems, ROS are primarily generated through mitochondrial oxidative phosphorylation. Within the mitochondria, the electron transport chain (ETC) is a significant source of superoxide radicals, particularly at complexes I and III. Additional sources of ROS include peroxisomal fatty acid metabolism, cytochrome P450 enzymes, and NADPH oxidases (NOX), especially in immune cells during the respiratory burst.
2. Oxidative Damage and Cellular ConsequencesOxidative damage refers to the harmful effects caused by ROS and reactive nitrogen species (RNS), which are generated as byproducts of normal cellular metabolism or introduced through external factors such as ultraviolet radiation, pollutants, and xenobiotics ³³. Although ROS, such as superoxide anions (O₂⁻), hydrogen peroxide (H₂O₂), and hydroxyl radicals (•OH), play essential roles in cell signaling, immune response, and homeostasis, their excessive accumulation leads to OS. This imbalance triggers the oxidation of crucial biomolecules, including lipids, proteins, and nucleic acids, thereby impairing cellular structure and function. Lipid peroxidation is one of the primary manifestations of oxidative damage, where polyunsaturated fatty acids in the cell membrane undergo chain reactions initiated by ROS. The resultant peroxides and aldehydes, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), compromise membrane fluidity and integrity, disrupt ion gradients, and can lead to increased cellular permeability or lysis. In mitochondria, oxidative damage to phospholipids such as cardiolipin impairs membrane potential and the electron transport chain, amplifying ROS generation and contributing to mitochondrial dysfunction and cell death.
Proteins are also highly susceptible to oxidative modifications, especially at sulfur-containing residues like cysteine and methionine. Oxidation can result in protein misfolding, fragmentation, and the formation of insoluble aggregates, as seen in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. These alterations not only abrogate protein enzymatic activity and receptor function but also burden the cellular quality control systems, including the ubiquitin-proteasome pathway and autophagy machinery. Persistent oxidative protein damage can overwhelm these proteolytic systems, leading to the accumulation of toxic aggregates and triggering cellular stress responses. Moreover, oxidative damage to nucleic acids, particularly DNA, is among the most deleterious effects of ROS. Oxidative lesions such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) can cause base mispairing, strand breaks, and genomic instability, which are closely linked to carcinogenesis, aging, and various degenerative conditions. If not effectively repaired by base excision repair (BER) or nucleotide excision repair (NER) mechanisms, such lesions may lead to mutations in oncogenes or tumor suppressor genes, driving malignant transformation.
Oxidative damage represents a pivotal molecular insult that disrupts the integrity and function of essential cellular components. While cells are equipped with intricate antioxidant defenses to counteract ROS and repair oxidative lesions, overwhelming OS leads to a cascade of detrimental effects ranging from macromolecular damage to cell death and tissue dysfunction. Understanding the mechanisms of oxidative damage and its consequences is crucial not only for elucidating disease pathogenesis but also for developing targeted antioxidant therapies and preventive strategies.
3.Mechanisms Linking Oxidative Stress and Brain FunctionOS plays a central role in the regulation and dysregulation of brain function through multiple interconnected mechanisms that influence neuronal signaling, synaptic plasticity, mitochondrial activity, neuroinflammation, and cellular survival ³⁴. The brain is particularly susceptible to oxidative damage due to its high oxygen demand, abundant lipid content, and relatively low levels of antioxidant defenses compared to other organs. Neurons, being post-mitotic cells with limited regenerative capacity, are especially vulnerable to cumulative oxidative insults. Under physiological conditions, ROS modulates neurotransmission, synaptic strength, and long-term potentiation (LTP), which is crucial for learning and memory ³⁵. However, excessive ROS production, often triggered by mitochondrial dysfunction, environmental toxins, neuroinflammation, or excitotoxicity, disrupts these regulatory processes and contributes to cognitive deficits and neurodegeneration.
One key mechanism linking OS to altered brain function is mitochondrial impairment. Mitochondria are not only the main source of ATP in neurons but also the principal site of ROS generation. Under stress conditions, impaired electron transport chain activity leads to electron leakage and increased superoxide formation. In turn, excessive mitochondrial ROS damage mitochondrial DNA, proteins, and membrane lipids, impairing oxidative phosphorylation and initiating a vicious cycle of energy failure and further ROS production. This mitochondrial dysfunction disrupts neuronal metabolism, inhibits axonal transport, and promotes apoptotic signaling through the release of cytochrome c and activation of caspases. Another critical mechanism involves the oxidation of proteins and lipids essential for synaptic integrity. Oxidative modifications of ion channels, neurotransmitter receptors, and membrane transporters can alter calcium homeostasis, neurotransmitter release, and synaptic plasticity. Lipid peroxidation in neuronal membranes affects membrane fluidity, receptor mobility, and synaptic vesicle fusion, thereby impairing communication between neurons. In addition, oxidative damage to cytoskeletal proteins like tau promotes aggregation and microtubule destabilization, contributing to axonal transport deficits and synaptic loss observed in neurodegenerative diseases.
OS also plays a role in altering neurogenesis and synaptic remodeling, particularly in the hippocampus, a region critical for learning and memory ³⁶. Under physiological conditions, ROS help regulate stem cell proliferation and differentiation. However, chronic OS impairs adult neurogenesis, reduces dendritic spine density, and disrupts the expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) ³⁷. Reduced BDNF levels are associated with cognitive deficits and mood disorders, and oxidative suppression of BDNF signaling has been observed in both experimental models and patients with depression and Alzheimer’s disease ³⁸. Moreover, epigenetic modifications induced by OS, such as DNA methylation, histone oxidation, and non-coding RNA regulation, can lead to long-lasting changes in gene expression patterns that influence neuronal function and disease susceptibility.
OS profoundly affects brain function through a variety of interconnected mechanisms involving mitochondrial dysfunction, synaptic impairment, neuroinflammation, transcriptional dysregulation, and impaired neuroplasticity. While ROS plays essential roles in normal neuronal signaling, its excessive accumulation disrupts critical cellular processes and contributes to the pathogenesis of various neuropsychiatric and neurodegenerative disorders. Understanding these mechanisms provides insight into potential therapeutic targets, such as antioxidants, mitochondrial stabilizers, and Nrf2 activators, which may help restore redox balance and preserve cognitive and emotional health.
Oxidative Stress in Major Psychiatric DisordersOS has emerged as a central biological mechanism implicated in the pathophysiology of major psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders ³⁹. These conditions, though clinically heterogeneous, share overlapping molecular disturbances characterized by redox imbalance, chronic low-grade inflammation, and neuroprogression. OS refers to a state in which the production of ROS and reactive nitrogen species (RNS) overwhelms the antioxidant defense systems, leading to damage to cellular components such as DNA, lipids, and proteins. In the central nervous system (CNS), where neurons have high metabolic demands and limited regenerative capacity, oxidative insults are particularly deleterious. Accumulating evidence from clinical, preclinical, and postmortem studies supports the involvement of OS in structural brain changes, synaptic dysfunction, neuroinflammation, and altered neurotransmission observed in psychiatric disorders.
In major depressive disorder, OS is closely linked to disrupted neuroplasticity and reduced neurogenesis, particularly in the hippocampus, a brain region critical for mood regulation and cognitive processing ⁴⁰. OS contributes to hypothalamic-pituitary-adrenal (HPA) axis dysregulation, further aggravating the neuroendocrine abnormalities observed in depression ⁴¹. Importantly, antidepressant treatment appears to modulate oxidative balance, with some agents increasing antioxidant enzyme activity or reducing lipid peroxidation, suggesting that redox regulation may be a targetable mechanism in mood disorders.
In bipolar disorder, OS is thought to contribute to mood instability, cognitive decline, and progressive structural brain changes ⁴². During both manic and depressive episodes, patients with BD show elevated OS markers and reduced antioxidant capacity. Mitochondrial dysfunction—a major source of ROS—has been implicated in BD through genetic and functional studies, revealing impaired energy metabolism and increased oxidative burden.
In schizophrenia, OS is intricately linked to neurodevelopmental abnormalities, synaptic pruning deficits, and accelerated brain aging ¹⁹. Patients with schizophrenia exhibit increased levels of oxidative damage markers and reduced antioxidant enzymes in both peripheral blood and brain tissue.
Anxiety disorders, though less extensively studied in this context, also show associations with OS. Patients with generalized anxiety disorder, panic disorder, and post-traumatic stress disorder (PTSD) frequently exhibit elevated peripheral markers of lipid peroxidation and protein oxidation, along with reduced antioxidant enzyme levels.
Importantly, OS is not an isolated mechanism but interacts dynamically with neuroinflammation, mitochondrial dysfunction, impaired neurotrophic signaling, and excitotoxicity to create a self-perpetuating cycle of neuroprogression in psychiatric illness. The redox-inflammatory feedback loop, in which ROS activate pro-inflammatory cytokines and vice versa, plays a critical role in maintaining a state of chronic subclinical inflammation often observed in psychiatric patients.
OS represents a converging pathological process that bridges genetic vulnerability, environmental stressors, and neurobiological dysfunction in major psychiatric disorders. Through its impact on mitochondrial function, synaptic plasticity, neuroinflammation, and cellular resilience, oxidative stress contributes to the onset, severity, and progression of mental illness. Continued research into redox biology not only enhances our understanding of psychiatric pathophysiology but also opens new avenues for biomarker development and personalized treatment strategies aimed at restoring oxidative balance and improving long-term outcomes in affected individuals.
Antioxidant Therapies in PsychiatryAntioxidant therapies have emerged as a promising adjunctive approach in the management of psychiatric disorders, grounded in a growing body of evidence implicating OS as a common underlying mechanism in conditions such as major depressive disorder, bipolar disorder, schizophrenia, and anxiety-related disorders ⁴³. OS, characterized by the overproduction of ROS and/or a decline in antioxidant defense mechanisms, leads to cellular damage, mitochondrial dysfunction, and impaired neuroplasticity—all of which are central to the neuropathology of mental illnesses. Conventional psychotropic medications primarily target neurotransmitter systems; however, they often fail to fully address the neuroprogressive and inflammatory dimensions of these disorders ⁴⁴. This has driven interest in antioxidants as adjunctive treatments aimed at restoring redox balance, protecting neural structures, and potentially improving both psychiatric symptoms and cognitive function. Several natural and synthetic antioxidant compounds, including NAC, omega-3 fatty acids, vitamins C and E, coenzyme Q10, curcumin, and polyphenols, have shown varying degrees of efficacy in clinical and preclinical psychiatric research.
N-acetylcysteine is one of the most extensively studied antioxidant agents in psychiatry. It serves as a precursor to glutathione, the brain’s most abundant intracellular antioxidant, and exhibits direct free radical scavenging properties ⁴⁵. Beyond its antioxidant role, NAC modulates glutamatergic transmission, reduces neuroinflammation, and enhances neurogenesis. Clinical trials have demonstrated that NAC may improve depressive symptoms, negative symptoms in schizophrenia, and even reduce cravings and impulsivity in substance use disorders. In bipolar disorder, adjunctive NAC has shown significant effects on mood stabilization, particularly in reducing depressive episodes ⁴⁶. Its favorable safety profile and potential to target multiple neurobiological pathways make NAC an attractive candidate for broader therapeutic application, although more large-scale, long-term studies are needed to confirm its efficacy and optimal dosing in various psychiatric populations.
Omega-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are another class of compounds with antioxidant and anti-inflammatory properties that have garnered attention for their neuropsychiatric benefits ⁴⁷. These fatty acids are crucial components of neuronal membranes and modulate membrane fluidity, receptor function, and signal transduction. Through their capacity to reduce lipid peroxidation, enhance antioxidant enzyme expression, and inhibit pro-inflammatory cytokine production, omega-3s exert neuroprotective effects that may alleviate psychiatric symptoms. Vitamins with antioxidant properties, notably vitamin C and vitamin E, have also been investigated for their potential psychiatric benefits ⁴⁸. Vitamin C, a water-soluble antioxidant, plays an essential role in neurotransmitter synthesis, iron metabolism, and protection against oxidative neuronal injury. It has been associated with improvements in mood, anxiety, and cognitive performance, although controlled studies remain limited. Vitamin E, a lipid-soluble antioxidant, helps prevent lipid peroxidation in cell membranes and has been evaluated as an adjunctive therapy in schizophrenia, particularly for reducing tardive dyskinesia—a motor side effect of antipsychotic medications believed to involve oxidative mechanisms. However, results from vitamin E trials have been inconsistent, and high-dose supplementation may carry risks, underscoring the need for careful dosing and patient selection.
Coenzyme Q10 (ubiquinone), a mitochondrial cofactor involved in electron transport and ATP production, also exhibits potent antioxidant activity ⁴⁹. It has shown promise in reducing fatigue, depressive symptoms, and cognitive impairment, particularly in individuals with neurodegenerative and mood disorders marked by mitochondrial dysfunction.
Antioxidant therapies offer a biologically plausible and potentially impactful avenue for adjunctive treatment in major psychiatric disorders. By targeting oxidative stress—a shared pathophysiological feature across mood, psychotic, and anxiety disorders—these interventions may support neuroprotection, enhance cognitive function, and augment symptom improvement. While promising, further high-quality, mechanistically informed clinical trials are essential to establish the efficacy, safety, and personalization of antioxidant strategies in routine psychiatric care.
Challenges and Future DirectionsDespite significant advances in understanding the role of OS in psychiatric disorders, several challenges hinder the translation of mechanistic insights into effective clinical interventions. One of the foremost limitations lies in the heterogeneity of psychiatric diagnoses. Conditions such as major depressive disorder, bipolar disorder, and schizophrenia encompass diverse symptom profiles and biological substrates, making it difficult to generalize findings across patient populations. Furthermore, studies examining OS markers often yield inconsistent results, partly due to methodological variability in biomarker selection, sample handling, and the timing of assessment relative to illness phase or treatment status. The lack of standardized protocols for measuring OS and antioxidant capacity contributes to discrepancies across studies and impedes meta-analytic synthesis.
Another significant challenge is the limited understanding of causality. While elevated oxidative stress markers are consistently reported in psychiatric patients, it remains unclear whether these are causal factors in disease pathogenesis or secondary consequences of illness progression, medication effects, or lifestyle factors such as poor diet, sleep disturbances, and substance use. Moreover, many antioxidant interventions have shown modest or mixed efficacy in clinical trials, raising questions about dosing, treatment duration, CNS penetration, and interindividual variability in response. The absence of validated redox-based biomarkers to guide patient selection or monitor therapeutic response further complicates the integration of antioxidant strategies into clinical practice.
A critical barrier to progress is the underrepresentation of longitudinal and mechanistically rich studies. Most existing research is cross-sectional, which limits inferences about the temporal relationship between oxidative stress and clinical outcomes. In addition, few studies examine the interaction of OS with other pathophysiological domains such as neuroinflammation, mitochondrial dysfunction, HPA axis dysregulation, and gut-brain axis alterations, all of which may act synergistically to drive psychiatric symptomatology. Integrative, systems-level approaches that combine omics technologies (e.g., metabolomics, transcriptomics), neuroimaging, and clinical phenotyping are urgently needed to delineate redox-related subtypes of psychiatric illness.
Another promising direction involves exploring redox modulation during critical developmental windows, particularly adolescence and early adulthood, when psychiatric disorders often emerge and brain systems are especially vulnerable to oxidative damage. Preventive strategies aimed at preserving redox balance during high-risk periods may help delay or attenuate disease onset. Furthermore, elucidating the role of sex differences, genetic polymorphisms, and epigenetic modifications in modulating OS responses will be essential to tailor interventions across diverse populations.
In conclusion, while OS offers a compelling mechanistic framework for understanding and treating psychiatric disorders, substantial work remains to overcome current limitations. Multidisciplinary collaboration, standardized biomarker protocols, longitudinal study designs, and precision medicine approaches will be pivotal in advancing the field. With continued research, oxidative stress may shift from a peripheral biomarker of disease burden to a core therapeutic target in psychiatry, offering new hope for more effective and biologically grounded treatments.

Conclusion

OS has emerged as a critical pathophysiological component in a wide spectrum of psychiatric disorders, including depression, bipolar disorder, schizophrenia, and anxiety-related conditions. Mounting evidence from preclinical, clinical, and biomarker studies underscores the multifaceted role of redox imbalance in contributing to neuronal dysfunction, synaptic plasticity deficits, neuroinflammation, and mitochondrial impairment—features that collectively drive the onset and progression of mental illness. Although OS was once viewed as a peripheral correlate of psychiatric disease, it is now increasingly recognized as a central mechanism that intersects with other biological systems, including the immune, endocrine, and metabolic pathways.
The therapeutic potential of targeting OS has gained momentum, with antioxidant agents such as N-acetylcysteine (NAC), omega-3 fatty acids, and polyphenols showing promising, albeit variable, results as adjunctive treatments. These compounds offer a means of addressing the neurobiological underpinnings of psychiatric illness beyond symptom suppression, potentially modifying disease trajectory and improving functional outcomes. However, significant challenges remain, particularly in establishing causality, identifying clinically meaningful biomarkers, and designing personalized interventions that account for individual variability in redox biology.
Future progress in this field hinges on an integrative, multidisciplinary approach that combines molecular research, neuroimaging, clinical phenotyping, and longitudinal study designs. Incorporating OS markers into diagnostic frameworks, monitoring systems, and treatment algorithms could pave the way for a more biologically informed and precision-based psychiatry. Ultimately, by deepening our understanding of oxidative mechanisms and refining antioxidant-based therapies, we can advance toward more effective, comprehensive, and preventive strategies for managing psychiatric disorders.

Declarations

References

1. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3-10
   PubMed Google Scholar
2. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-72.
   PubMed Google Scholar
3. Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914-27.
   PubMed Google Scholar
4. Monroe SM, Harkness KL. Major Depression and its recurrences: life course matters. Annu Rev Clin Psychol. 2022;18:329-57.
   PubMed Google Scholar
5. Lau N, Waldbaum S, Parigoris R, O’Daffer A, Walsh C, Colt SF, et al. eHealth and mHealth psychosocial interventions for youths with chronic illnesses: systematic review. JMIR Pediatr Parent. 2020;3(2):e22329.
   PubMed Google Scholar
6. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation. 2013;10:43.
   PubMed Google Scholar
7. Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020;25(7):1270-6.
   PubMed Google Scholar
8. Jorgensen A, Baago IB, Rygner Z, Jorgensen MB, Andersen PK, Kessing LV, et al. Association of oxidative stress-induced nucleic acid damage with psychiatric disorders in adults: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79(9):920-31.
   PubMed Google Scholar
9. Erdal H, Günaydın F, Karaoğlanoğlu S. Oxidative stress in asthma. Aksaray Univ J Sport Health Res. 2023;4(1):62-70.
   PubMed Google Scholar
10. Özcan O, Erdal H, Çakırca G, Yönden Z. Oxidative stress and its impacts on intracellular lipids, proteins and DNA. J Clin Exp Invest. 2015;6(3):331-6.
    PubMed Google Scholar
11. Genc SO, Erdal H. Effect of mode of delivery on neonatal oxidative stress and dynamic thiol–disulfide homeostasis. J Int Med Res. 2023;51(10):03000605231202145.
    PubMed Google Scholar
12. Erdal H, Bekmezci M. Evaluation of dynamic thiol/disulfide homeostasis and ischemia-modified-albumin levels in cord blood of newborns to patients with oxytocin-induced labor. Aksaray Univ J Sport Health Res. 2022;3(2):193-202.
    PubMed Google Scholar
13. Erdal H, Ciftciler R, Tuncer SC, Ozcan O. Evaluation of dynamic thiol-disulfide homeostasis and ischemia-modified albumin levels in patients with chronic lymphocytic leukemia. J Investig Med. 2023;71(1):62-6.
    PubMed Google Scholar
14. Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24(8):1583.
    PubMed Google Scholar
15. Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol. 2014;12(2):140-7.
    PubMed Google Scholar
16. Andreazza AC, Kauer-Sant’Anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111(2-3):135-44.
    PubMed Google Scholar
17. Michel TM, Pulschen D, Thome J. The role of oxidative stress in depressive disorders. Curr Pharm Des. 2012;18(36):5890-9.
    PubMed Google Scholar
18. Tsai M-C, Huang T-L. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord. 2015;173:22-6.
    PubMed Google Scholar
19. Ma J, Yan L, Guo T, Yang S, Ni D, Liu Y, et al. A pilot study of biomarkers of oxidative stress in serum and schizophrenia. Psychiatry Res. 2020;284:112757.
    PubMed Google Scholar
20. Bajpai A, Verma AK, Srivastava M, Srivastava R. Oxidative stress and major depression. J Clin Diagn Res. 2014;8(12):CC04.
    PubMed Google Scholar
21. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1178-83.
    PubMed Google Scholar
22. Lin C-H, Li T-M, Huang Y-J, Chen S-J, Lane H-Y. Differential impacts of endogenous antioxidants on clinical symptoms and cognitive function in acute and chronic schizophrenia patients. Int J Neuropsychopharmacol. 2023;26(8):576-83.
    PubMed Google Scholar
23. Bortolasci CC, Turner A, Mohebbi M, Liu ZS, Ashton M, Gray L, et al. Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. J Psychiatr Res. 2021;142:376-83.
    PubMed Google Scholar
24. Edemann-Callesen H, Bernhardt N, Hlusicka EB, Hintz F, Habelt B, Winter R, et al. Supplement treatment with NAC and omega-3 polyunsaturated fatty acids during pregnancy partially prevents schizophrenia-related outcomes in the poly I:C rat model. Antioxidants. 2023;12(5):1068.
    PubMed Google Scholar
25. Demirtas MS, Erdal H. Evaluation of thiol disulfide balance in adolescents with vitamin B12 deficiency. Ital J Pediatr. 2023;49(1):3.
    PubMed Google Scholar
26. Demirtas MS, Erdal H. Evaluation of thiol-disulfide homeostasis and oxidative stress parameters in newborns receiving phototherapy. J Investig Med. 2023;71(3):183-90.
    PubMed Google Scholar
27. Demirtas MS, Erdal H, Kilicbay F, Tunc G. Association between thiol-disulfide hemostasis and transient tachypnea of the newborn in late-preterm and term infants. BMC Pediatr. 2023;23(1):135.
    PubMed Google Scholar
28. Demirtas MS, Kilicbay F, Erdal H, Tunc G. Oxidative stress levels and dynamic thiol-disulfide balance in preterm newborns with bronchopulmonary dysplasia. Lab Med. 2023;54(6):587-92.
    PubMed Google Scholar
29. Erdal H, Demirtas MS, Kilicbay F, Tunc G. Evaluation of oxidative stress levels and dynamic thiol-disulfide balance in patients with retinopathy of prematurity. Curr Eye Res. 2023;48(11):1026-33.
    PubMed Google Scholar
30. Erdal H, Turgut F. Thiol/disulfide homeostasis as a new oxidative stress marker in patients with Fabry disease. J Investig Med. 2023;71(8):865-70.
    PubMed Google Scholar
31. Genc SO, Erdal H. Effect of mode of delivery on neonatal oxidative stress and dynamic thiol-disulfide homeostasis. J Int Med Res. 2023;51(10):3000605231202145.
    PubMed Google Scholar
32. Hassan W, Noreen H, Castro-Gomes V, Mohammadzai I, Rocha JB, Landeira-Fernandez J. Association of oxidative stress with psychiatric disorders. Curr Pharm Des. 2016;22(20):2960-74.
    PubMed Google Scholar
33. Zhang XY, Yao JK. Oxidative stress and therapeutic implications in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:197-9.
    PubMed Google Scholar
34. Velmurugan GV, Vekaria HJ, Hartz AMS, Bauer B, Hubbard WB. Oxidative stress alters mitochondrial homeostasis in isolated brain capillaries. Fluids Barriers CNS. 2024;21(1):81.
    PubMed Google Scholar
35. Bansal Y, Kuhad A. Mitochondrial dysfunction in depression. Curr Neuropharmacol. 2016;14(6):610-8.
    PubMed Google Scholar
36. Oz M, Erdal H. A TNF-alpha inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation. Behav Brain Res. 2024;466:114995.
    PubMed Google Scholar
37. Wei C, Sun Y, Chen N, Chen S, Xiu M, Zhang X. Interaction of oxidative stress and BDNF on executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology. 2020;111:104473.
    PubMed Google Scholar
38. Carboni E, Carta AR. BDNF alterations in brain areas and the neurocircuitry involved in the antidepressant effects of ketamine in animal models, suggest the existence of a primary circuit of depression. J Integr Neurosci. 2022;21(5):144.
    PubMed Google Scholar
39. Luca M, Guzik T, Luca A. Oxidative stress as a link between cerebrocardiovascular and psychiatric disorders. Oxid Med Cell Longev. 2020;2020:5685317.
    PubMed Google Scholar
40. Huang CY, Chiang WC, Yeh YC, Fan SC, Yang WH, Kuo HC, et al. Effects of virtual reality-based motor control training on inflammation, oxidative stress, neuroplasticity and upper limb motor function in patients with chronic stroke: a randomized controlled trial. BMC Neurol. 2022;22(1):21.
    PubMed Google Scholar
41. McCann SM, Antunes-Rodrigues J, Franci CR, Anselmo-Franci JA, Karanth S, Rettori V. Role of the hypothalamic pituitary adrenal axis in the control of the response to stress and infection. Braz J Med Biol Res. 2000;33:1121-31.
    PubMed Google Scholar
42. Madireddy S, Madireddy S. Therapeutic interventions to mitigate mitochondrial dysfunction and oxidative stress-induced damage in patients with bipolar disorder. Int J Mol Sci. 2022;23(3):1844.
    PubMed Google Scholar
43. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294-321.
    PubMed Google Scholar
44. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 1995;21(4):567-77.
    PubMed Google Scholar
45. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021;19(8):1202-24.
    PubMed Google Scholar
46. Smaga I, Frankowska M, Filip M. N-acetylcysteine as a new prominent approach for treating psychiatric disorders. Br J Pharmacol. 2021;178(13):2569-94.
    PubMed Google Scholar
47. Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. 2015;29(6):2207-22.
    PubMed Google Scholar
48. Borges-Vieira JG, Cardoso CKS. Efficacy of B-vitamins and vitamin D therapy in improving depressive and anxiety disorders: a systematic review of randomized controlled trials. Nutr Neurosci. 2023;26(3):187-207.
    PubMed Google Scholar
49. Majmasanaye M, Mehrpooya M, Amiri H, Eshraghi A. Discovering the potential value of coenzyme Q10 as an adjuvant treatment in patients with depression. J Clin Psychopharmacol. 2024;44(3):232-9.
    PubMed Google Scholar

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →

About This Article

Received:

May 14, 2025

Accepted:

June 16, 2025

Published Online:

June 26, 2025